We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Umbilical Cord Blood Therapy in Children With CP

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02025972
First Posted: January 1, 2014
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
CHA University
Information provided by (Responsible Party):
MinYoung Kim, M.D., Bundang CHA Hospital
December 29, 2013
January 1, 2014
October 12, 2017
December 2013
November 15, 2015   (Final data collection date for primary outcome measure)
  • Cytokine analysis [ Time Frame: 12 months ]
    Cytokine analysis
  • Changes in Standardized Gross Motor Function [ Time Frame: Baseline - 3 months - 6 months - 12months ]
    GMFM (Gross Motor Function Measure) is a standardized measurement tool for assessing gross motor function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100, higher value means better gross motor function).
  • Changes in Motor Performance [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    GMPM (Gross Motor Performance Measure) is a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0~100, higher value means better motor quality).
  • Changes in Cognitive Neurodevelopmental Outcome [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scale (range: 0~178; worst: 0, best: 178)
  • Changes in Motor Neurodevelopmental Outcome [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scale (range: 0~112; worst: 0, best: 112)
Same as current
Complete list of historical versions of study NCT02025972 on ClinicalTrials.gov Archive Site
  • Changes in Gross Motor Function Classification System [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    GMFCS (Gross Motor Function Classification System) is a five-level classification system based on self-initiated movement, with emphasis on sitting, transfers, and mobility (level I: walks without limitations, ll: walks with limitations, III: walks using a hand-held mobility device, IV: self-mobility with limitations, V: transported in a manual wheelchair).
  • Changes in Functional Independence in Daily Activities [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher score means more independent performance in daily activities.
  • Changes in Functional Performance in Daily Activities [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Pediatric Evaluation of Disability Inventory (PEDI) is used to assess functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). PEDI consists of 2 scales such as Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) and each scale is composed of 3 domains including self care, mobility, and social function.
  • Changes in Upper Extremity Function [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    QUEST (Quality of Upper Extremity Skills Test) is a standardized measurement tool for assessing upper extremity function consisting of sub-scales; dissociated movement, grasps, weight bearing, and protective extension. QUEST ranges from 0 (or below 0 in grasp section) to 100 and higher values mean better upper extremity function.
  • Changes in Visual Perception Test [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Visual perception function will be assessed with one of 3 tools such as DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). Higher value means better visual perception ability.
  • Changes in Selective Movement of Lower Extremity [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    SCALE (Selective Control Assessment of Lower Extremity) is a measurement tool of selective movement of hip, knee, ankle, subtalar joint and toes. Selective voluntary motor control is graded at each joint as normal (2 points), impaired (1 point) or unable (0 point).
  • Changes in Spasticity [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Muscle spasticity of biceps, hip adductors, hamstrings and heel cords is graded according to modified Ashworth scale (MAS).
  • Changes in Dynamic Component of Spasticity [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Dynamic component of spasticity in bilateral hamstrings is graded using modified Tardieu scale (MTS).
  • Changes in Muscle Strength [ Time Frame: Baseline - 3 months - 6 months - 12 months ]
    Muscle strength is measured using summated scores of manual muscle test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 ~ 160). Higher score means stronger muscle power.
  • Changes in Brain MRI [ Time Frame: Baseline - 12 months ]
    Diffusion Tensor Image (DTI) of brain MRI (magnetic resonance imaging) provides quantitative information about the microscopic integrity of white matter. White matter normally possesses a high degree of diffusion anisotropy than gray matter. Fractional anisotropy (FA) will be measured and it ranges from 0 to 1. Higher FA value means more integrity of white matter.
  • Changes in Brain 18F-FDG PET [ Time Frame: Baseline - 12 months ]
    18F-FDG PET (Positron emission tomography with fluorine-18-fluorodeoxyglucose) imaging will be performed twice prior to and 12 months after UCB therapy.
  • Changes in EEG [ Time Frame: Baseline - 12 months ]
    Electroencephalography (EEG) will be performed twice prior to and 12 months after UCB therapy.
  • Changes in EP [ Time Frame: Baseline - 12 months ]
    Median, tibial somatosensory evoked potential (SEP), visual evoked potential (VEP), auditory evoked potential (AEP) will be performed twice prior to and 12 months after UCB therapy.
  • Number of adverse events and participants with those adverse events [ Time Frame: 12 months ]
    The numbers of adverse events and subjects with those serious adverse events within each group; A serious adverse event is any untoward medical occurrence that at any dose: results in death or is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or causes a congenital anomaly/birth defect.
Same as current
Not Provided
Not Provided
 
Allogeneic Umbilical Cord Blood Therapy in Children With CP
Changes in Cytokines and Functional Outcomes of Allogeneic Cord Blood Therapy in Children With Cerebral Palsy
This open-label study aims to analyze cytokines related to clinical outcomes of allogeneic umbilical cord blood therapy for children with cerebral palsy.

Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP.

Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries.

Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP. This study was designed to find cytokines relevant to UCB therapy.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cerebral Palsy
Procedure: Allogeneic umbilical cord blood therapy
Experimental: Allogeneic umbilical cord blood therapy
Allogeneic umbilical cord blood therapy
Intervention: Procedure: Allogeneic umbilical cord blood therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
November 15, 2015
November 15, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with cerebral palsy
  • Age of ≤15 years
  • Mismatch in HLA-A, B, and DR ≤2, and total nucleated cell count ≥3x10^7/kg. If the cell count is less than given values, more than 1 unit could be used.
  • Decision of participation in the study by and acquisition of informed consent from the subject's representative
  • Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry

Exclusion Criteria:

  • Current aspiration pneumonia
  • Known genetic disease
  • History of hypersensitivity reaction to any study drugs pertinent to the study
  • Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents
  • Uncontrolled hypertension defined as systolic blood pressure >115 mmHg and/or diastolic blood pressure >70 mmHg
  • Hepatic impairment defined as asparate aminotransferase (AST) >55 IU/L and/or alanine aminotransferase (ALT) >45 IU/L
  • Renal impairment defined as creatinine (Cr) ≥1.2 mg/dL
  • Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy
  • Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient
Sexes Eligible for Study: All
up to 15 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT02025972
UCBCP
No
Not Provided
Not Provided
MinYoung Kim, M.D., Bundang CHA Hospital
MinYoung Kim, M.D.
CHA University
Principal Investigator: MinYoung Kim, M.D., Ph.D. CHA University
Bundang CHA Hospital
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP